Core Viewpoint - MoonLake Immunotherapeutics, Inc. is facing a class action lawsuit for investors who purchased securities during the specified class period, indicating potential corporate wrongdoing [1][3]. Company Overview - MoonLake is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's primary drug candidate is sonelokimab (SLK), aimed at treating hidradenitis suppurativa (HS) [3]. Drug Development - SLK's commercial prospects hinge on its ability to demonstrate efficacy in HS that is comparable or superior to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for the same indication [3].

Core Points - Nutex Health, Inc. is facing a class action lawsuit for investors who purchased securities between August 8, 2024, and August 14, 2025, with a deadline to file a lead plaintiff motion by October 21, 2025 [1] - Blue Orca Capital issued a short report on July 22, 2025, alleging that Nutex is exposed to litigation risk due to its association with HaloMD, which is involved in a fraudulent scheme against insurance companies [3] - Following the release of the Blue Orca report, Nutex's stock price dropped by $11.18 per share, or 10.05%, closing at $100.01 per share on the same day [3] Legal Representation - The Portnoy Law Firm is representing investors in claims related to corporate misconduct and offers complimentary case evaluations [2][4] - The founding partner of the Portnoy Law Firm has successfully recovered over $5.5 billion for investors in the past [4]

Core Viewpoint - A class action has been initiated against Cepton, Inc. for securities fraud during the specified class period from July 29, 2024, to January 6, 2025, with a deadline for lead plaintiff motion filings set for December 8, 2025 [1]. Group 1 - The Portnoy Law Firm is advising investors who purchased Cepton securities during the class period to take legal action [1][2]. - Investors can contact attorney Lesley F. Portnoy for a complimentary case evaluation and to discuss their legal rights [2]. - The investigation focuses on potential securities fraud or unlawful business practices by Cepton, Inc. and its officers or directors [2]. Group 2 - The Portnoy Law Firm has a history of representing investors in claims related to corporate wrongdoing, having recovered over $5.5 billion for aggrieved investors [3].

Core Viewpoint - Fortress Biotech Inc. is under investigation for possible securities fraud following a significant stock price drop after the FDA issued a Complete Response Letter regarding its New Drug Application for CUTX-101, citing manufacturing deficiencies [3]. Group 1: Legal Actions - The Portnoy Law Firm has initiated an investigation into Fortress Biotech Inc. and may file a class action on behalf of investors [1]. - Investors are encouraged to contact the Portnoy Law Firm to discuss their legal rights and options for pursuing claims to recover losses [2]. Group 2: Company Developments - On October 1, 2025, Fortress Biotech and its subsidiary, Cyprium Therapeutics, announced the FDA's Complete Response Letter related to CUTX-101, which noted cGMP deficiencies at the manufacturing facility [3]. - Following the announcement of the CRL, the stock price of Fortress Biotech experienced a decline [3].

Core Points - CTO Realty Growth, Inc. is facing a class action lawsuit for investors who purchased securities between February 8, 2021, and June 24, 2025, with a deadline to file a lead plaintiff motion by October 7, 2025 [1] - Wolfpack Research published a report on June 25, 2025, accusing CTO of misleading investors regarding dividend sustainability and engaging in questionable financial practices, resulting in a stock price drop of $0.98 per share, or 5.42%, closing at $17.10 [3] Legal Context - The Portnoy Law Firm is representing investors in claims related to corporate misconduct, offering complimentary case evaluations and options for recovering losses [2][4] - The founding partner of the Portnoy Law Firm has a track record of recovering over $5.5 billion for investors affected by corporate wrongdoing [4]

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Skechers U.S.A., Inc. (“Skechers” or “the Company”) (NYSE: SKX) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Skechers investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorn ...

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into KinderCare Learning Companies, Inc. for possible securities fraud, potentially leading to a class action lawsuit for investors who suffered losses [1][2]. Financial Performance - KinderCare reported an operating loss of $89.3 million for Q4 and the full year of 2024, a significant decline from a profit of $48.7 million in the same quarter the previous year, primarily due to increased equity-based compensation expenses and reduced COVID-19-related reimbursements [3]. - The company's financial guidance for 2025 did not meet market expectations, resulting in a 22.17% decline in stock price on the following trading day [4]. Legal Actions - Investors are encouraged to contact attorney Lesley F. Portnoy for a complimentary case evaluation regarding their legal rights and options for recovering losses [2][5].

Group 1 - The Portnoy Law Firm has initiated an investigation into D-Wave Quantum Inc. for possible securities fraud and may file a class action on behalf of investors [1][3] - Block & Leviton LLP is also investigating D-Wave Quantum Inc. following a report by Kerrisdale Capital, which questions the credibility of D-Wave's technology and claims it is more of a marketing strategy than a genuine advancement in quantum computing [3] - D-Wave Quantum's stock experienced a decline of up to 6% during intraday trading after the release of the Kerrisdale Capital report [3] Group 2 - The Portnoy Law Firm offers a complimentary case evaluation for investors seeking to recover losses and encourages them to contact attorney Lesley F. Portnoy [2][4] - The founding partner of the Portnoy Law Firm has successfully recovered over $5.5 billion for aggrieved investors [4]

Core Viewpoint - Geron Corporation is facing a class action lawsuit due to alleged misleading statements regarding its revenue outlook and the market potential of its drug Rytelo, leading to significant stock price decline [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Geron securities between February 28, 2024, and February 25, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Geron - The lawsuit claims that Geron made false statements about its revenue outlook and growth potential, while downplaying risks related to seasonality and macroeconomic conditions [3]. - It is alleged that Geron's optimistic portrayal of Rytelo's launch was overstated, with significant impacts from seasonality, competition, and monitoring requirements [3]. - The lawsuit also states that Rytelo lacked sufficient market awareness to achieve meaningful penetration, particularly among first-line patients [3]. Group 3: Financial Impact - On February 26, 2025, Geron announced its fourth-quarter financial results for fiscal year 2024, revealing stagnation in Rytelo's growth attributed to seasonality, competitive pressures, and limited awareness [4]. - Following this announcement, Geron's stock price fell by more than 32% [4].

The lawsuit further alleges that, on February 5, 2025, Skyworks announced its financial results for the first quarter of fiscal year 2025 and issued lower-than-expected revenue guidance for the second quarter, attributing the disappointing outlook to an increasingly competitive landscape. Following this news, the price of Skyworks stock declined by more than 24%, according to the complaint. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm repr ...